These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27062684)

  • 1. Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study.
    Azzollini J; Scuvera G; Bruno E; Pasanisi P; Zaffaroni D; Calvello M; Pasini B; Ripamonti CB; Colombo M; Pensotti V; Radice P; Peissel B; Manoukian S
    Eur J Intern Med; 2016 Jul; 32():65-71. PubMed ID: 27062684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Spectrum of
    Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
    Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
    Manchanda R; Burnell M; Gaba F; Desai R; Wardle J; Gessler S; Side L; Sanderson S; Loggenberg K; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Legood R; Beller U; Tomlinson I; Menon U; Jacobs I
    BJOG; 2020 Feb; 127(3):364-375. PubMed ID: 31507061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
    Bonaïti B; Alarcon F; Andrieu N; Bonadona V; Dondon MG; Pennec S; Stoppa-Lyonnet D; Bonaïti-Pellié C; Perdry H
    J Med Genet; 2014 Feb; 51(2):114-21. PubMed ID: 24343917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.
    Varesco L; Viassolo V; Viel A; Gismondi V; Radice P; Montagna M; Alducci E; Della Puppa L; Oliani C; Tommasi S; Caligo MA; Vivanet C; Zuradelli M; Mandich P; Tibiletti MG; Cavalli P; Lucci Cordisco E; Turchetti D; Boggiani D; Bracci R; Bruzzi P; Bonelli L
    Breast; 2013 Dec; 22(6):1130-5. PubMed ID: 24011770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
    Long KC; Kauff ND
    Curr Opin Oncol; 2011 Sep; 23(5):526-30. PubMed ID: 21734577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario.
    Dos Santos Vidal R; Hawrysh A; Walia JS; Davey S; Feilotter H
    J Mol Diagn; 2016 May; 18(3):362-369. PubMed ID: 26941049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of Poland.
    Janiszewska H; Haus O; Lauda-Swieciak A; Pasińska M; Laskowski R; Szymański W; Górski B; Lubiński J
    Clin Genet; 2003 Dec; 64(6):502-8. PubMed ID: 14986830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.
    Møller P; Stormorken A; Holmen MM; Hagen AI; Vabø A; Mæhle L
    Breast Cancer Res Treat; 2014 Apr; 144(3):607-14. PubMed ID: 24619173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
    Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
    JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement.
    Am Fam Physician; 2020 Feb; 101(4):233-238. PubMed ID: 32053325
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
    Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
    Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.